Tumor Biology

, Volume 37, Issue 1, pp 1217–1227 | Cite as

Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization

  • Fateme Sadri-Ardalani
  • Mahdi Shabani
  • Mohammad Mehdi Amiri
  • Motahareh Bahadori
  • Shaghayegh Emami
  • Ali Reza Sarrafzadeh
  • Farzaneh Noutash-Haghighat
  • Mahmood Jeddi-Tehrani
  • Fazel Shokri
Original Article


Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15–20 % of breast cancer patients and is an appropriate target for immunotherapy in these patients. Monoclonal antibodies (mAbs) specific to HER2 are currently applied to treat breast cancer patients with HER2 overexpression. Active immunization with HER2 DNA or protein has been considered as a suitable alternative. The aim of this study is to evaluate anti-HER2 antibody response in serum of mice immunized with DNA constructs containing full extracellular domain (fECD) or subdomains of human HER2. Four extracellular subdomains and also fECD of HER2 were cloned into pCMV6-Neo vector. Different groups of Balb/C mice were immunized with HER2 DNA constructs and boosted with HER2 recombinant protein. The anti-HER2 antibody was subsequently determined by ELISA, flow cytometry, and immunohistochemistry. Anti-HER2 antibody was detected only in serum of mice immunized with fECD DNA. None of HER2 extracellular subdomains induced appreciable levels of anti-HER2 antibody. However, boosting with fECD or extracellular subdomain III (DIII) recombinant protein resulted in enhanced anti-HER2 fECD as well as anti-HER2 subdomain antibody responses. In this regard, almost all (99 %) of HER2-overexpressing BT474 cells could be detected by serum antibody from mice immunized with HER2 subdomain DNA and boosted with recombinant HER2 protein by flow cytometry. Similarly, serum of mice immunized with DIII DNA construct and boosted with recombinant DIII protein could also recognize these cells, but to a lesser extent (50 %). Our findings suggest that combination of HER2 DNA and protein immunization could effectively induce anti-HER2 antibody response in Balb/C mice.


Breast cancer DNA immunization Extracellular domains HER2 Immunotherapy Recombinant protein 



We would like to thank Farhad Hosseini for technical help in the animal lab. This work was partly supported by grants from Avicenna Research Institute and Tehran University of Medical Sciences.

Conflicts of interest



  1. 1.
    Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1:247–55.PubMedGoogle Scholar
  2. 2.
    Busch DR, Choe R, Durduran T, Yodh AG. Towards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics. PET Clin. 2013;8:345–65.CrossRefGoogle Scholar
  3. 3.
    Yan HX, Cheng P, Wei HY, Shen GB, Fu LX, Ni J, et al. Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing vegfr2. Oncol Rep. 2013;29:1510–6.PubMedGoogle Scholar
  4. 4.
    Ahmed S, Sami A, Xiang J. Her2-directed therapy: current treatment options for her2-positive breast cancer. Breast Cancer. 2015. doi: 10.1007/s12282-015-0587-x.Google Scholar
  5. 5.
    Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW, et al. Structure of the extracellular region of her2 alone and in complex with the herceptin fab. Nature. 2003;421:756–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Iqbal N. Human epidermal growth factor receptor 2 (her2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014. doi: 10.1155/2014/852748.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015;41:69–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Wong DJ, Hurvitz SA. Recent advances in the development of anti-her2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014;2:122.PubMedPubMedCentralGoogle Scholar
  10. 10.
    O’Sullivan CC, Smith KL. Therapeutic considerations in treating her2-positive metastatic breast cancer. Curr Breast Cancer Rep. 2014;6:169–82.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of her-2/neu. Int J Cancer. 2003;107:976–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, et al. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol Immunother. 2010;59:715–27.CrossRefPubMedGoogle Scholar
  14. 14.
    You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 2001;61:3704–11.PubMedGoogle Scholar
  15. 15.
    Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10:3153–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Webster RG, Robinson HL. DNA vaccines: a review of developments. BioDrugs. 1997;8:273–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Marchini C, Kalogris C, Garulli C, Pietrella L, Gabrielli F, Curcio C, et al. Tailoring DNA vaccines: designing strategies against her2-positive cancers. Front Oncol. 2013. doi: 10.3389/fonc.2013.00122.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic balb/c mice. J Immunol. 2000;165:5133–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, et al. Activity of DNA vaccines encoding self or heterologous HER-2/neu in HER-2 or neu transgenic mice. Cell Immunol. 2006;240:96–106.CrossRefPubMedGoogle Scholar
  20. 20.
    Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, et al. Protection against mammary tumor growth by vaccination with full-length, modified human erbb-2 DNA. Int J Cancer. 1999;81:748–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res. 2004;64:2858–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res. 1998;58:1965–71.PubMedGoogle Scholar
  23. 23.
    Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 2000;7:703–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res. 2014;20:2910–21.CrossRefPubMedGoogle Scholar
  25. 25.
    Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/cea DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013;11:62.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013;24:1740–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Shabani M, Hemmati A, Zandemami M, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, et al. Cloning, expression and characterization of recombinant human fc receptor like 1, 2 and 4 molecules. Iran J Biotechnol. 2013;11:182–92.CrossRefGoogle Scholar
  28. 28.
    Boyle JS, Silva A, Brady JL, Lew AM. DNA immunization: induction of higher avidity antibody and effect of route on t cell cytotoxicity. Proc Natl Acad Sci U S A. 1997;94:14626–31.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yu S, Wang F, Fan L, Wei Y, Li H, Sun Y, et al. Bap31, a promising target for the immunotherapy of malignant melanomas. J Exp Clin Cancer Res. 2015;34:36.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dorken B, et al. Her2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology. 2012;1:1537–45.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Orlandi F, Guevara-Patino JA, Merghoub T, Wolchok JD, Houghton AN, Gregor PD. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine. 2011;29:3646–54.CrossRefPubMedGoogle Scholar
  32. 32.
    Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, et al. Her-2/neu mediated down-regulation of MHC class i antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother. 2009;58:653–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005;12:1324–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Tahmasebi F, Kazemi T, Amiri MM, Khoshnoodi J, Mahmoudian J, Bayat AA, et al. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. Immunotherapy. 2014;6:43–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317–28.CrossRefPubMedGoogle Scholar
  37. 37.
    Benjamin DC, Berzofsky JA, East IJ, Gurd FR, Hannum C, Leach SJ, et al. The antigenic structure of proteins: a reappraisal. Annu Rev Immunol. 1984;2:67–101.CrossRefPubMedGoogle Scholar
  38. 38.
    Mooij P, Koopman G, Drijfhout JW, Nieuwenhuis IG, Beenhakker N, Koestler J, et al. Synthetic long peptide booster immunization in rhesus macaques primed with replication competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. J Gen Virol. 2015. doi: 10.1099/vir.0.000074.PubMedGoogle Scholar
  39. 39.
    Palmer J, Bell M, Darko C, Barnewall R, Keane-Myers A. Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241. Pathog Dis. 2014;72:138–42.PubMedGoogle Scholar
  40. 40.
    Muthumani K, Wise MC, Broderick KE, Hutnick N, Goodman J, Flingai S, et al. HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo. PLoS One. 2013;8, e84234.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gu Y, Zhan B, Yang Y, Yang X, Zhao X, Wang L, et al. Protective effect of a prime-boost strategy with the Ts87 vaccine against Trichinella spiralis infection in mice. Biomed Res Int. 2014;2014:326860.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Wang YQ, Zhang HH, Liu CL, Wu H, Wang P, Xia Q, et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol. 2013;17:9–17.CrossRefPubMedGoogle Scholar
  43. 43.
    Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother. 2012;61:1857–67.CrossRefPubMedGoogle Scholar
  44. 44.
    Nakashima H, Fujisawa T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Transl Med. 2010;8:116.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Lu Y, Ouyang K, Fang J, Zhang H, Wu G, Ma Y, et al. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine. 2009;27:5411–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu + metastatic breast cancer in mice. Breast Cancer Res. 2005;7:R580–8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Nguyen-Hoai T, Baldenhofer G, Ahmed MS, Pham-Duc M, Gries M, Lipp M, et al. CCL19 (elc) improves TH1-polarized immune responses and protective immunity in a murine HER2/neu DNA vaccination model. J Gene Med. 2012;14:128–37.CrossRefPubMedGoogle Scholar
  48. 48.
    Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Vu MD, Lipp M, et al. CCL21 (slc) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther. 2012;19:69–76.CrossRefPubMedGoogle Scholar
  49. 49.
    Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Sayed Ahmed MS, Dorken B, et al. Ccl19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther. 2012;19:880–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Fateme Sadri-Ardalani
    • 1
    • 2
  • Mahdi Shabani
    • 1
  • Mohammad Mehdi Amiri
    • 1
  • Motahareh Bahadori
    • 1
  • Shaghayegh Emami
    • 1
  • Ali Reza Sarrafzadeh
    • 3
  • Farzaneh Noutash-Haghighat
    • 1
  • Mahmood Jeddi-Tehrani
    • 1
  • Fazel Shokri
    • 1
    • 2
  1. 1.Monoclonal Antibody Research CenterAvicenna Research Institute, ACECRTehranIran
  2. 2.Department of Immunology, School of Public HealthTehran University of Medical SciencesTehranIran
  3. 3.Department of PathologyKhatam Al Anbia HospitalTehranIran

Personalised recommendations